Tag Archives: orphan drugs

FDA grants orphan drug designation to Nintedanib for Systemic Sclerosis

Boehringer Ingelheim’s nintedanib has been approved as orphan drug for the treatment of systemic sclerosis (SSc), also called scleroderma. FDA has taken an inevitable step forward in prevention and cure of Scleroderma, including associated interstitial lung disease. Sc is a rare disease causing scratches over skin, lungs and other organs, resulting into disabilility. Almost 2 million of people are suffering from SSC, out of which, 90%  cpatients have  been diagnosed with scarring in lungs. SSC holds a record of 35% of deaths caused by all the disease-related deaths in the world.

Rare diseases are also known as Orphan diseases. These diseases are generally categorized as chronic, degenerative, and life-threatening. The rare diseases normally include certain cancers, metabolic conditions, diseases of the nervous system and musculoskeletal disorders, which are extremely life-threatening. As per the official definition, rare diseases are classified as those that affect fewer than 200,000 in the United States and less than 5 in 10,000 in the EU. These two regions form a dominant portion of the global market for orphan drugs.


For Free Sample of Global Orphan Drug Clinical Pipeline Reports Contact: avinash@kuickresearch.com
Or Visit:  Global Orphan Drug Market Future Outlook 2020